Western blot shows lysate of C2C12 mouse myoblast cell line. PVDF membrane was probed with 0.25 µg/mL of Goat Anti-Mouse CDO Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2429) followed by ...read more
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Immunogen affinity purified
Reconstitute at 0.2 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for CDO Antibody [Unconjugated]
Cdon homolog (mouse)
cell adhesion molecule-related/down-regulated by oncogenes
surface glycoprotein, Ig superfamily member
Mouse CDO is a 190 kDa member of the Ig/FN-type III repeat subfamily of transmembrane (TM) proteins. The extracellular region contains five Ig-like domains and three FN-III modules. The molecule forms cis-complexes with itself and the related molecule termed BOC. Mouse CDO extracellular domain shares 95% and 85% aa identity with the corresponding regions of rat and human CDO, respectively.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our CDO Antibody [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.